europass	Curriculum Vitae Niccolò Bolli
PERSONAL INFORMATION	Niccolò Bolli Italian Nationality
CURRENT POSITIONS	Associate Professor of Hematology at University of Milan Consultant in Hematology at Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
WORK EXPERIENCE	
2020-Present	 Associate Professor of Hematology and Consultant in Hematology University of Milan - Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy Research activity on genomics of hematological malignancies, particularly multiple myeloma and myeloid malignancies. Study of mutations responsible for disease pathogenesis and evolution both in pre-clinical phases and after treatment. Application of recent acquisitions on genomics of hematological malignancies for classification and prognostic purposes. Single cell sequencing for the study of disease evolution and subclonal heterogeneity. Development of diagnostic tests based on next-generation sequencing and other second-generation molecular techniques. Head of the laboratory of molecular diagnostics of hematological neoplasms. Clinical activity for inpatients and outpatients within the neoplastic hematology service. Head of the multiple myeloma service within the hematology unit.
2015-2020	Associate Professor of Hematology and Consultant in Hematology University of Milan - Fondazione IRCCS Istituto Nazionale per lo Studio e la Cura dei Tumori di Milano Business or sector: Academia/Hospital
2011-2015	 Academic Clinical Lecturer/Honorary Clinical Fellow in Hematology University of Cambridge - Addenbrooke's Hospital, Cambridge, UK Research activity on genomics of hematological malignancies, particularly multiple myeloma and myeloid malignancies. Whole exome sequencing of single and paired samples of multiple myeloma to show significant mutations at diagnosis and Study of mutations responsible for disease pathogenesis and evolution both in pre-clinical phases and after treatment. In vitro and in vivo functional validation of RNA splicing gene mutations in myelodysplastic syndromes. Clinical activity for inpatient and outpatient neoplastic hematology service
2007-2011	 Post-doctoral fellow Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA Research activity on biology and genetics of myeloid malignancies. Creation of transient and stable zebrafish models of NPMc+ AML Forward genetic screens in zebrafish to identify genes required for maintenance of definitive hematopoiesis Use of high-resolution SNP arrays to identify genes disrupted in human myelodisplastic syndromes



Business or sector: Academia/Hospital

2001-2007 Trainee in hematology and then PhD student

University of Perugia, Italy

- Research activity on biology and genetics of myeloid malignancies.
 - study of mechanisms of altered NPMc+ subcellular transport in human acute myeloid leukemia (AML)
 - study and validation of new diagnostic techniques for NPMc+ AML.
 - Study of the cell of origin of NPMc+ AML
- Clinical activity for inpatients and outpatients within the neoplastic hematology service

Business or sector: Academia/Hospital

EDUCATION AND TRAINING

- 2019 Italian National Academic Qualification as Full Professor (Abilitazione Scientifica Nazionale, Settore concorsuale 06/D3, abilitato come professore di I fascia)
 Ministry of education and scientific research
- 2013 Italian National Academic Qualification as Associate Professor (Abilitazione Scientifica Nazionale, Settore concorsuale 06/D3, abilitato come professore di Il fascia)
 Ministry of education and scientific research
- 2005-2010 Ph. D. University of Perugia
- 2001-2005 Board certified in Hematology University of Perugia
- 1995-2001 M.D. University of Perugia 110/110 cum laude

PERSONAL SKILLS

Mother tongue Italian UNDERSTANDING **SPEAKING** WRITING Other languages Spoken Spoken Listening Reading production interaction C2 English C2 C2 C2 C2 A2 A2 French B1 B1 A1 Common European Framework of Reference for Languages I have excellent communication skills that I have acquired during my career Communication skills as associate professor and lecturer at national and international meetings. Teaching Organisational / managerial skills 2015-Present: Associate Professor of Hematology at the University of Milan "Statale", with 120 hours/year of teaching, tutoring and clinical-practical activities in hematology and molecular biology to medical and life sciences students, PhD students,

registrars.



Responsible for the integrated course "System diseases II" of the International Medical School, University of Milan

Responsible for the integrated course "Scienze Cliniche" of the degree in Denal Hygene, University of Milan

Responsible for the curriculum in oncology of the degree in Medical Biotechnology and Molecular Medicine, University of Milan

- 2019: Organizer of the course "Next generation sequencing in cancer and beyond" for PhD students in translational medicine of the XXXIV cycle" of the University of Milan.
- 2018-2019: Member of the PhD committee of the XXXIV and XXXV cycle of the PhD program in translational medicine of the University of Milan.
- 2012-2013 Instructor at the Wellcome Trust Advanced Course (Hinxton, UK): "Molecular Pathology and Diagnosis of Cancer".
- 2011-2015 Clinical Lecturer in Hematology at the University of Cambridge, involved in lecturing and tutoring students of the Cambridge Medical School. Specifically, lecturer in the "Pathology of malignant haematology 1 and 2 courses.

Experience in student examination, supervision and mentoring

- 2015-Present: As an associate professor of hematology at the University of Milan I have served as an extremal examiner for 9 PhD students of the Open University (UK), Leuven University (BE), University of Hasselt (BE), University San Raffaele (IT), University of Turin (IT), University of Padova (IT). I currently am supervisor of 1 PhD student from university San Raffaele and 3 from University of Milan.
- 2015-Present: As an associate professor of hematology at the University of Milan I have been supervising students of the medical school, students in life sciences and hematology trainees. I have personally supervised 8 students to their medical degree, 4 students for their medical biotechnology degrees, and 3 hematology trainees to their board certification.
- 2013-2015 As a clinical lecturer at the University of Cambridge I have been supervising PhD students (2), as well as MPhil (1) and MSc (1) students.

Editorial and reviewing activities

- Reviewer: Blood, Leukemia, Haematologica, BMC genomics, Oncotarget, Blood Advances, Clinical Cancer Research, Cancer Research, Nature Communications, Trends in Cancer, Bioinformatics, Journal of Immunology Research, Science Advances, Molecular and Cell Therapy, FEBS Journal, British Journal of Hematology, American Journal of Hematology.
- Editor: 2022-Present: Member of the editorial board of Clinical and Experimental Medicine

2019: Guest editor of the issue on "tumor microenvironment" of Frontiers in Oncology.

2014-2020: Associate Editor of the Onco-hematology section of Tumori Journal

Grant reviewer: The Wellcome Trust, the Lady Tata Memorial Trust, the Key Kendall Leukemia Fundation, the institute National du



Cancer, the EEA Research Programme 2014-2021, the Research Foundation, Flanders (FWO), the European Hematology Association (EHA), the Italian Society of Experimental Hematology (SIES), the Austrian Science Fund.

Honorary Positions

2023-present	Member of the steering committee of the yearly meeting "Under 40 in Hematology – Giovani ematologi a confronto"		
2021-2023:	Member of the Research Foundation, Flanders (FWO) Review College		
2021-2024	Member of the Grants and Fellowship Committee of the European Hematology Association (EHA)		
2018-2023	Counsellor of the Italian Society of Experimental Hematology (SIES)		
2018-present	Member of the European Myeloma Network (EMN) and the EHA scientific Working Group on myeloma.		

```
Digital skills
```

	SELF ASSESSMENT					
	Information	Communic	Content	Safety	Problem	
	processing	ation	creation		solving	
	Proficient	Proficient	Proficient	Proficient	Proficient	
	User	User	User	User	User	
Digital compatences. Calf accompany and						

Digital competences - Self-assessment grid

Driving license Type B

ADDITIONAL INFORMATION

Publications

Total citations: 15,573. H-index: 40 (Scopus, Nov 2023)

- 1. Platonova, N. *et al.* The Potential of JAG Ligands as Therapeutic Targets and Predictive Biomarkers in Multiple Myeloma. *Int. J. Mol. Sci.* (2023).
- Favasuli, V. K. *et al. DIS3* depletion in multiple myeloma causes extensive perturbation in cell cycle progression and centrosome amplification. *haematol* (2023).
- Fattizzo, B. *et al.* Immunomodulatory cytokines and clonal dynamics in low-risk myelodysplastic syndromes patients treated with luspatercept. *American J Hematol* 98, E345–E348 (2023).
- 4. Cattaneo, D. *et al.* Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort. *Ann Hematol* (2023).
- Taiana E, Bandini C, Favasuli VK, et al. Activation of long non-coding RNA NEAT1 leads to survival advantage of multiple myeloma cells by supporting a positive regulatory loop with DNA repair proteins. haematol. 2023;108(1):219– 233.
- Sauta E, Robin M, Bersanelli M, et al. Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. JCO. 2023; JCO.22.01784.
- Pettine L, Bortolotti M, Fattizzo B, et al. Response to SARS-CoV-2 vaccination and antibodies persistence in multiple myeloma patients. Hematological Oncology. 2023;41(1):210–212.
- 8. Moscvin M, Liacos CI, Chen T, et al. Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy. Blood Cancer J. 2023;13(1):31.



- Haertle L, Barrio S, Munawar U, et al. Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma. Clinical Cancer Research. 2023;29(1):279–288.
- Diamond BT, Ziccheddu B, Maclachlan KH, et al. Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures. Blood. 2023;blood.2022018244.
- Todoerti K, Ronchetti D, Favasuli V, et al. DIS3 mutations in multiple myeloma impact the transcriptional signature and clinical outcome. haematol. 2022;107(4):921–932.
- Solimando AG, Da Vià MC, Bolli N, Steinbrunn T. The Route of the Malignant Plasma Cell in Its Survival Niche: Exploring "Multiple Myelomas." Cancers. 2022;14(13):3271.
- 13. Ronchetti D, Favasuli VK, Silvestris I, et al. Expression levels of NONO, a nuclear protein primarily involved in paraspeckles function, are associated with several deregulated molecular pathways and poor clinical outcome in multiple myeloma. Discov Onc. 2022;13(1):124.
- Oben B, Cosemans C, Geerdens E, et al. The Dynamics of Nucleotide Variants in the Progression from Low–Intermediate Myeloma Precursor Conditions to Multiple Myeloma: Studying Serial Samples with a Targeted Sequencing Approach. Cancers. 2022;14(4):1035.
- Matera A, Marella A, Maeda A, et al. Single-Cell RNA Sequencing for the Detection of Clonotypic V(D)J Rearrangements in Multiple Myeloma. IJMS. 2022;23(24):15691.
- Manzoni M, Bosi A, Fabris S, et al. Clinical, Morphological and Clonal Progression of VEXAS Syndrome in the Context of Myelodysplasia Treated with Azacytidine. Clin Hematol Int. 2022;4(1–2):52–55.
- 17. Da Vià MC, Lionetti M, Marella A, et al. MGUS and clonal hematopoiesis show unrelated clinical and biological trajectories in an older population cohort. Blood Advances. 2022;6(21):5702–5706.
- Botta C, Gigliotta E, Paiva B, et al. Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant. Hematological Oncology. 2022;40(5):987–998.
- Ziccheddu B, Da Vià MC, Lionetti M, et al. Functional Impact of Genomic Complexity on the Transcriptome of Multiple Myeloma. Clin Cancer Res. 2021;27(23):6479–6490.
- Vittoria L, Bozzi F, Capone I, et al. A rare biclonal Hairy Cell Leukemia disclosed by an integrated diagnostic approach: A case report. Cytometry. 2021;100(6):692–694.
- Truger MS, Duell J, Zhou X, et al. Single- and double-hit events in genes encoding immune targets before and after T cell–engaging antibody therapy in MM. Blood Advances. 2021;5(19):3794–3798.
- 22. Todoerti K, Taiana E, Puccio N, et al. Transcriptomic Analysis in Multiple Myeloma and Primary Plasma Cell Leukemia with t(11;14) Reveals Different Expression Patterns with Biological Implications in Venetoclax Sensitivity. Cancers. 2021;13(19):.
- Sacco A, Federico C, Todoerti K, et al. Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity. Blood. 2021;138(18):1705–1720.
- 24. Rustad EH, Nadeu F, Angelopoulos N, et al. mmsig: a fitting approach to accurately identify somatic mutational signatures in hematological malignancies. Commun Biol. 2021;4(1):424.
- 25. Ruiz-Heredia Y, Ortiz-Ruiz A, Samur MK, et al. Pathogenetic and Prognostic Implications of Increased Mitochondrial Content in Multiple Myeloma. Cancers. 2021;13(13):3189.
- 26. Rossi M, Meggendorfer M, Zampini M, et al. Clinical relevance of clonal hematopoiesis in persons aged ≥80 years. Blood. 2021;138(21):2093–2105.
- 27. Oben B, Froyen G, Maclachlan KH, et al. Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities. Nat Commun. 2021;12(1):1861.



- 28. Musto P, Engelhardt M, Caers J, et al. 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. haematol. 2021;106(11):.
- 29. Maclachlan KH, Rustad EH, Derkach A, et al. Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma. Nature Communications. 2021;12(1):5172.
- Lionetti M, Da Vià MC, Albano F, et al. Genomics of Smoldering Multiple Myeloma: Time for Clinical Translation of Findings? Cancers. 2021;13(13):3319.
- Holstein SA, Bahlis N, Bergsagel PL, et al. The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma. Transplantation and Cellular Therapy. 2021;27(10):807– 816.
- 32. Haertle L, Barrio S, Munawar U, et al. Cereblon enhancer methylation and IMiD resistance in multiple myeloma. Blood. 2021;138(18):1721–1726.
- Bolli N, Sgherza N, Curci P, et al. What Is New in the Treatment of Smoldering Multiple Myeloma? Journal of Clinical Medicine. 2021;10(3):.
- Bianchi G, Czarnecki PG, Ho M, et al. ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment. Blood Cancer Discov. 2021;2(4):338–353.
- Bersanelli M, Travaglino E, Meggendorfer M, et al. Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes. JCO. 2021;39(11):1223–1233.
- 36. Bassani B, Tripodo C, Portararo P, et al. CD40 Activity on Mesenchymal Cells Negatively Regulates OX40L to Maintain Bone Marrow Immune Homeostasis Under Stress Conditions. Front. Immunol. 2021;12:662048.
- Ziccheddu B, Biancon G, Bagnoli F, et al. Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma. Blood Advances. 2020;4(5):830–844.
- 38. Rustad EH, Yellapantula V, Leongamornlert D, et al. Timing the initiation of multiple myeloma. Nature Communications. 2020;11(1):613–14.
- 39. Rustad EH, Yellapantula VD, Glodzik D, et al. Revealing the Impact of Structural Variants in Multiple Myeloma. Blood Cancer Discov. 2020;1(3):258–273.
- 40. Monti V, Bagnoli F, Bolli N, et al. A new case of myelodysplastic syndrome associated with t(3;3)(q21;q26) and inv(11)(p15q22). Tumori. 2020;1–5.
- 41. Maura F, Dodero A, Carniti C, et al. CDKN2A deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS). haematol. 2020;106(11):2918–2926.
- 42. Manzoni M, Pompa A, Fabris S, et al. Limits and Applications of Genomic Analysis of Circulating Tumor DNA as a Liquid Biopsy in Asymptomatic Forms of Multiple Myeloma. HemaSphere. 2020;4(4):e402.
- 43. Manzoni M, Marchica V, Storti P, et al. Application of Next-Generation Sequencing for the Genomic Characterization of Patients with Smoldering Myeloma. Cancers. 2020;12(5):1332.
- 44. Da Vià MC, Ziccheddu B, Maeda A, et al. A Journey Through Myeloma Evolution: From the Normal Plasma Cell to Disease Complexity. HemaSphere. 2020;4(6):e502.
- 45. D'Agostino M, Zaccaria GM, Ziccheddu B, et al. Early Relapse Risk in Newly Diagnosed Multiple Myeloma Patients Characterized by Next-Generation Sequencing. Clin Cancer Res. 2020;clincanres.0951.2020.
- 46. Bolli N, Martinelli G, Cerchione C. The molecular pathogenesis of multiple myeloma. Hematol Rep. 2020;12(3):.
- Bolli N, Genuardi E, Ziccheddu B, et al. Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time? Front. Oncol. 2020;10:1046.
- 48. Alvarez EG, Baez-Ortega A, Zamora J, et al. Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition. Nat Genet. 2020;409(3):860–14.
- 49. Yellapantula V, Hultcrantz M, Rustad EH, et al. Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma. Blood Cancer J. 2019;9(12):101–9.



- Walker BA, Mavrommatis K, Wardell CP, et al. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019;33(1):159–170.
- Maura F, Degasperi A, Nadeu F, et al. A practical guide for mutational signature analysis in hematological malignancies. Nature Communications. 2019;10(1):2969.
- 52. Maura F, Bolli N, Rustad EH, et al. Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A Review. JAMA Oncol. 2019;
- Maura F, Bolli N, Angelopoulos N, et al. Genomic landscape and chronological reconstruction of driver events in multiple myeloma. Nature Communications. 2019;10(1):3835.
- 54. Maura F, Agnelli L, Leongamornlert D, et al. Integration of Transcriptional and Mutational Data Simplifies the Stratification of Peripheral T-Cell Lymphoma. Am J Hematol. 2019;
- Walker BA, Mavrommatis K, Wardell CP, et al. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018;132(6):587–597.
- 56. Maura F, Petljak M, Lionetti M, et al. Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines. Leukemia. 2018;32(4):1044–1048.
- 57. Corre J, Cleynen A, Robiou du Pont S, et al. Multiple myeloma clonal evolution in homogeneously treated patients. Leukemia. 2018;364:1046.
- 58. Collord G, Martincorena I, Young MD, et al. Recurrent histone mutations in T-cell acute lymphoblastic leukaemia. Br J Haematol. 2018;
- Bolli N, Maura F, Minvielle S, et al. Genomic patterns of progression in smoldering multiple myeloma. Nature Communications. 2018;9(1):3363.
- Bolli N, Biancon G, Moarii M, et al. Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia. 2018;32(12):2604–2616.
- Wang M, Zhang S, Chuang S-S, et al. Angioimmunoblastic T cell lymphoma: novel molecular insights by mutation profiling. Oncotarget. 2017;8(11):17763– 17770.
- 62. Soldarini M, Farina L, Genderini A, Bolli N. A rare case of atypical chronic lymphocytic leukaemia presenting as nephrotic syndrome. BMJ Case Rep. 2017;2017:bcr-2016-218850.
- Grove CS, Bolli N, Manes N, et al. Rapid parallel acquisition of somatic mutations after NPM1 in acute myeloid leukaemia evolution. Br J Haematol. 2017;176(5):825–829.
- Gerstung M, Papaemmanuil E, Martincorena I, et al. Precision oncology for acute myeloid leukemia using a knowledge bank approach. Nat Genet. 2017;49(3):332–340.
- 65. Bolli N, Barcella M, Salvi E, et al. Next-generation sequencing of a family with a high penetrance of monoclonal gammopathies for the identification of candidate risk alleles. Cancer. 2017;123(19):3701–3708.
- 66. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med. 2016;374(23):2209–2221.
- 67. Mupo A, Seiler M, Sathiaseelan V, et al. Hemopoietic-specific Sf3b1-K700E knock-in mice display the splicing defect seen in human MDS but develop anemia without ring sideroblasts. Leukemia. 2016;31(3):720–727.
- McKerrell T, Moreno T, Ponstingl H, et al. Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies. Blood. 2016;128(1):e1-9.
- Maura F, Guidetti A, Pellegrinelli A, et al. High-dose chemotherapy followed by autologous transplantation may overcome the poor prognosis of diffuse large Bcell lymphoma patients with MYC/BCL2 co-expression. Blood Cancer J. 2016;6(11):e491.
- Maura F, Dodero A, Carniti C, Bolli N. Biology of peripheral T cell lymphomas Not otherwise specified: Is something finally happening? Pathogenesis. 2016;3(1):9–18.



- De Philippis C, Di Chio MC, Sabattini E, Bolli N. Bowel perforation from occult ileal involvement after diagnosis in a case of primary mediastinal large B-cell lymphoma. BMJ Case Rep. 2016;2016:.
- Bolli N, Li Y, Sathiaseelan V, et al. A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma. Blood Cancer J. 2016;6(9):e467.
- Clipson A, Wang M, de Leval L, et al. KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype. Leukemia. 2015;29(5):1177–1185.
- 74. Bolli N, Manes N, McKerrell T, et al. Characterization of gene mutations and copy number changes in acute myeloid leukemia using a rapid target enrichment protocol. Haematologica. 2015;100(2):214–222.
- Tubio JMC, Li Y, Ju YS, et al. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes. Science. 2014;345(6196):1251343–1251343.
- 76. Rashid NU, Sperling AS, Bolli N, et al. Differential and limited expression of mutant alleles in multiple myeloma. Blood. 2014;124(20):3110–3117.
- Nik-Zainal S, Wedge DC, Alexandrov LB, et al. Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer. Nat Genet. 2014;46(5):487– 491.
- 78. Ju YS, Alexandrov LB, Gerstung M, et al. Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer. Elife. 2014;3:.
- 79. Cooke SL, Shlien A, Marshall J, et al. Processed pseudogenes acquired somatically during cancer development. Nature Communications. 2014;5:.
- Bolli N, Avet-Loiseau H, Wedge DC, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nature Communications. 2014;5:2997.
- Sportoletti P, Varasano E, Rossi R, et al. The human NPM1 mutation A perturbs megakaryopoiesis in a conditional mouse model. Blood. 2013;121(17):3447– 3458.
- Conte N, Varela I, Grove C, et al. Detailed molecular characterisation of acute myeloid leukaemia with a normal karyotype using targeted DNA capture. Leukemia. 2013;27(9):1820–1825.
- 83. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–421.
- Payne EM, Bolli N, Rhodes J, et al. Ddx18 is essential for cell-cycle progression in zebrafish hematopoietic cells and is mutated in human AML. Blood. 2011;118(4):903–915.
- 85. Grabher C, Payne EM, Johnston AB, et al. Zebrafish microRNA-126 determines hematopoietic cell fate through c-Myb. Leukemia. 2011;25(3):506–514.
- Falini B, Martelli MP, Bolli N, et al. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? Blood. 2011;117(4):1109–1120.
- Bolli N, Payne EM, Rhodes J, et al. cpsf1 is required for definitive HSC survival in zebrafish. Blood. 2011;117(15):3996–4007.
- Bolli N, Payne EM, Grabher C, et al. Expression of the cytoplasmic NPM1 mutant (NPMc+) causes the expansion of hematopoietic cells in zebrafish. Blood. 2010;115(16):3329–3340.
- Falini B, Bolli N, Liso A, et al. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. Leukemia. 2009;23(10):1731–1743.
- Bolli N, De Marco MF, Martelli MP, et al. A dose-dependent tug of war involving the NPM1 leukaemic mutant, nucleophosmin, and ARF. Leukemia. 2009;23(3):501–509.
- Martelli MP, Manes N, Liso A, et al. A western blot assay for detecting mutant nucleophosmin (NPM1) proteins in acute myeloid leukaemia. Leukemia. 2008;22(12):2285–2288.
- Martelli MP, Manes N, Pettirossi V, et al. Absence of nucleophosmin leukaemic mutants in B and T cells from AML with NPM1 mutations: implications for the cell of origin of NPMc+ AML. Leukemia. 2008;22(1):195–198.



- Lo-Coco F, Cuneo A, Pane F, et al. Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia. Haematologica. 2008;93(7):1017–1024.
- Liso A, Castiglione F, Cappuccio A, et al. A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1). Haematologica. 2008;93(8):1219–1226.
- Liso A, Bogliolo A, Freschi V, et al. In human genome, generation of a nuclear export signal through duplication appears unique to nucleophosmin (NPM1) mutations and is restricted to AML. Leukemia. 2008;22(6):1285–1289.
- 96. Falini B, Martelli MP, Mecucci C, et al. Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice. Haematologica. 2008;93(5):775–779.
- 97. Falini B, Nicoletti I, Bolli N, et al. Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. Haematologica. 2007;92(4):519–532.
- Falini B, Lenze D, Hasserjian R, et al. Cytoplasmic mutated nucleophosmin (NPM) defines the molecular status of a significant fraction of myeloid sarcomas. Leukemia. 2007;21(7):1566–1570.
- 99. Bolli N, Nicoletti I, De Marco MF, et al. Born to be exported: COOH-terminal nuclear export signals of different strength ensure cytoplasmic accumulation of nucleophosmin leukemic mutants. Cancer Res. 2007;67(13):6230–6237.
- Ballanti S, Mastrodicasa E, Bolli N, et al. Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia. Nat Clin Pract Oncol. 2007;4(12):722–725.
- 101. Albiero E, Madeo D, Bolli N, et al. Identification and functional characterization of a cytoplasmic nucleophosmin leukaemic mutant generated by a novel exon-11 NPM1 mutation. Leukemia. 2007;21(5):1099–1103.
- Albiero E, Bolli N, Falini B, et al. Aberrant cytoplasmic expression of Cterminal-truncated NPM leukaemic mutant is dictated by tryptophans loss and a new NES motif. Leukemia. 2007;21(9):2052–4; author reply 2054; discussion 2055-6.
- 103. Pasqualucci L, Liso A, Martelli MP, et al. Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification. Blood. 2006;108(13):4146–4155.
- Falini B, Martelli MP, Bolli N, et al. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. Blood. 2006;108(6):1999–2005.
- 105. Falini B, Bolli N, Shan J, et al. Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood. 2006;107(11):4514–4523.
- 106. Falini B, Bigerna B, Pucciarini A, et al. Aberrant subcellular expression of nucleophosmin and NPM-MLF1 fusion protein in acute myeloid leukaemia carrying t(3;5): a comparison with NPMc+ AML. Leukemia. 2006;20(2):368–371.
- 107. Bolli N, Galimberti S, Martelli MP, et al. Cytoplasmic nucleophosmin in myeloid sarcoma occurring 20 years after diagnosis of acute myeloid leukaemia. Lancet Oncol. 2006;7(4):350–352.
- Tiacci E, Orvietani P-L, Bigerna B, et al. Tumor protein D52 (TPD52): a novel B-cell/plasma-cell molecule with unique expression pattern and Ca(2+)dependent association with annexin VI. Blood. 2005;105(7):2812–2820.
- Quentmeier H, Martelli MP, Dirks WG, et al. Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin. Leukemia. 2005;19(10):1760–1767.
- Bolli N, Di Ianni M, Simonetti S, et al. Treating two concurrent B-cell and Tcell lymphoid neoplasms with alemtuzumab monotherapy. Lancet Oncol. 2004;5(1):64–65.
- Book chapters
 "Anemie", "Emopoiesi clonale", "Alterazioni qualitative e quantitative dei leucociti", "Leucemia mieloide acuta" in: Manuale di Ematologia. A cura di P. Corradini e R. Foà. Edizioni Minerva Medica. III edizione, Torino 2020. ISBN: 978-88-7711-971-1.
 - 2. "Mieloma Multiplo: biologia, criteri diagnostici e prognostici" in: Seminari di



Ematologia Clinica. A cura di Alberto Bosi. Edizioni Internazionali, Pavia 2016. ISSN 2038-2839

- "The Molecular Pathogenesis of Haematological Cancers" in: Postgraduate Haematology, 7a edizione. A cura di A. Victor Hoffbrand, Douglas Higgs, Atul B. Mehta, David M. Keeling. Wiley: Oxford 2015. ISBN: 9781118854327.
- Member of the Scientific Committee of the 5th Italian edition of "Manuale Merck di diagnosi e terapia" (translated from the 18th English edition). Milano, Raffaello Cortina Editore Srl, 2008. ISBN: 9788847007079.
- "Leucemie acute dell'Adulto" in: Enciclopedia medica italiana UTET. (3rd update of the 2nd edition). L. Vella editore. - Firenze: USES, 2008. - ISBN 9788802080253.
- Grants awarded on a 2023-2024 Proof-of-conce competitive basis (ERC): "Perso
- 23-2024 Proof-of-concept Grant from the European Research Commission (ERC): "Personalized prognosis in smoldering myeloma through automated analysis of mutational signatures". EUR 150'000
 - 2023-2024 International Myeloma Society (IMS) and Paula and Rodger Riney Foundation Translational Research Award. "Functional screens on single-cell transcriptomes of genotypically-defined minimal residual disease cells to unravel specific vulnerabilities of treatment resistant multiple myeloma (FUTURE)". USD 248'940.
 - 2022-2026 Investigator Grant n. 25739 from the "associazione Italiana per la Ricerca sul Cancro". Title: Single-cell serial dissection of neoplastic clones in multiple myeloma to pinpoint ontogenesis, MRD and relapse. EUR 865'000
 - 2021-2023 Institutional grant from the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico. EUR 100'000
 - 2019-2024 Consolidator Grant from the European Research Commission (ERC): "spontaneous evolution and clonal heterogeneity in monoclonal gammopathies: from mechanisms of progression to clinical management – BECOMING". EUR 1'998'781
 - 2016-2018 My First AIRC grant from the Associazione Italiana per la Ricerca sul Cancro. EUR 188'000
 - 2012-2014 EHA fellowship from the European Haematology Association. EUR 72'000
 - 2012-2013 Starter grant for academic clinical lecturers from the Academy of Medical Sciences. GBP 30'000
 - 2009-2011 Leukemia and Lymphoma Society Career Development Program Special Fellow Award. USD 195'000
 - 2007-2009 American-Italian Cancer Foundation (AICF) International Fellowship Award. USD 70'000
 - 2005-2007 Federazione Italiana per la Ricerca sul Cancro (FIRC, Italian Federation for Cancer Research) Fellowship Award. EUR 45'000

Honors and awards 2013 First prize "Under 40 in Hematology – Giovani ematologi a confronto" promosso dalla Società Italiana di Ematologia. EUR 6'000

- 2012 Winner of the Young Scientist Award at the 17th meeting of the European Haematology Association with an abstract titled: "Whole Exome Sequencing Defines Clonal Architecture and Genomic Evolution in Multiple Myeloma". EUR 5000
- 2011 Winner of a Lady Tata Award for a project titled: "Genetc modifiers of the phenotypic landscape in JAK2^{V617F} myeloproliferative neoplasms". EUR 12'000



Niccolò Bolli

- 2006 Winner of the "Grazia Caiani Bartocci" prize from the Accademia Anatomico-Chirurgica of the University of Perugia in Mat 2006 with a project titled "Aspetti funzionali delle mutazioni del gene NPM1". EUR 4.000
- Invited Lectures at 20 national and international meetings
- 2023 2nd edition of the "La patologia plasmacellulare: updates and hot topics" (Oliena, 13th of October): "genomic structure in asymptomatic PC dyscrasias".
 - 2023 10th edition of the "giornate ematologiche Vicentine" (Vicenza, 12th October): Clinical and laboratory prognostic markers in myeloma",
 - 2023 Multiple myeloma 2023 meeting (Palermo, 21st September): "Genomic complexity along myeloma evolution".
 - 2023 8th workshop in translational hematology of the Italian Society of Experimental Hematology (SIES) Firenze 22nd of June: "The future of treatment of high-risk myeloma".
 - 2023 Fondazione Ghislieri (Pavia, 3rd May): Clonal and sub-clonal heterogeneity in multiple myeloma: what we can learn from single cell analysis.
 - 2023 Masterlcass in multiple myeloma (Milano, 27th April): The patient journey in third line and beyond
 - 2023 8th Heidelberg Myeloma Workshop (Heidelberg, 21st-23rd April): "Impact of Genomic Complexity on the Transcriptome of Multiple Myeloma"
 - 2023 3rd European Myeloma Network Meeting (Amsterdam, 19th-22nd April). "Myeloma precursors: MGUS and SMM: From genomics to microenvironment".
 - 2023 Erasmus MC Lecture series (Rotterdam, 27th March): "Genomics and evolution patterns of multiple myeloma spectrum conditions"
 - 2023 2º convegno regionale delegazione Sicilia Società Italiana di Ematologia (Catania, 6th-7th February): "Il paziente ad alto rischio – MIELOMA"
 - 2023 27th European Multiple Myeloma Academy (Wien, 27th-28th January): "Molecular events in the pathogenesis of myeloma".
 - 2022 Mieloma Multiplo: meet the experts (Pescara, 28th November): "Lesioni genetiche e progressione nel Mieloma Multiplo"
 - 2022 6th International Congress on Multiple Myeloma and Related Malignancies (Bari, 3rd-5th November) "Functional impact of genomic complexity on the transcriptome of multiple myeloma".
 - 2022 4th meeting of the Society of Hematologic Oncology (SOHO) Italy (Rome, 23rd-26th October) "Genomics of Smoldering Multiple Myeloma: Time for Clinical Translation of Findings?".
 - 2022 17th Myeloma and V Cell Therapy Workshop (Ostrava, 13th-14th October): "Genetic determinants of evolution in asymptomatic myeloma".
 - 2022 19th International Myeloma Society meeting (Los Angeles, CA, 25-27 August): meet the expert on "clonal hematopoiesis and myeloma".
 - 2022 Speaker at the educational event "Situazioni cliniche nel Mieloma Multiplo Recidivato Refrattario: evidenze ed esperienze" (Milano, 29 June): "la biologia del mieloma multiplo".
 - 2022 Speaker at the Master in management del Mieloma Multiplo by the European Myeloma Network (Torino, 19 May): "SMM: disease biology and evolution patterns".
 - 2022 Educational Workshop "recenti Updates e Approcci traslazionali nel



Mieloma Multiplo" (Palermo, 17 May): "The genomic landscape of plasma cell dyscrasias: determinants of myeloma evolution and treatment response".

- 2022 3rd European Myeloma Network Meeting (Online 6th-9th April). "From benign to malignant disease".
- 2022 Korean Society of Hematology (KSH) International Conference & 64th Annual Meeting (Online, 31st March-2nd April). "Evolution of myeloma from the normal plasma cell to disease complexity".
- 2022 Highlights from IMW (Bologna, 1-2 of february): "Evoluzione Genomica delle Discrasie Plasmacellulari" and "Alterazioni epigenetiche nel mieloma".
- 2022 26th European Multiple Myeloma Academy (Wien, 28-29 January): "Molecular events in the pathogenesis of myeloma".
- 2021 Speaker at the event "Mieloma Multiplo: il ruolo dell'MRD nell'era dell'immunoterapia" (online, 16th of December). "MRD nel mieloma: dalla biologia alla clinica"
- 2021 American Society of Hematology (Atlanta, 11-14th December): "Genetic evolution across the disease spectrum from MGUS to multiple myeloma".
- 2021 Speaker at the third SOHO Italian Conference (Rome, 27th-30th of September). Title of the talk: "Genetic profiling of Multiple Myeloma in novel agents era".
- 2021 Speaker at the "Myeloma Research Workshop from bedside to bench" Parma, Italy (online, 28th of September). "The genomics of smoldering myeloma"
- 2021 Chair of abstract session at the "International Myeloma Workshop" (Vienna, 8th –11th of September)
- 2021 Speaker at the virtual seminar "Multiple Myeloma: from diagnosis to the evaluation of the minimal residual disease" (online, 17th June) "Diagnostics of the Multiple Myeloma: the biological point of view".
- 2021 Speaker at the 2021 meeting of the European Hematology Association (online, 9th-17th of June). "Genetic drivers of progression from MGUS to myeloma".
- 2021 Speaker at the 8th Heidelberg Myeloma Workshop (online, 17th of April). ""Genomics of early MM"
- 2021 Speaker at the 2nd European Myeloma Network Meeting Amsterdam (online, 3rd of March). ""The role of the immunemicroenviroment in evolving myeloma precursor states"
- 2020 Speaker at the first SOHO Clinical And Biological School Of Multiple Myeloma (online, 15-17th of December). Title of the talk: "Molecular pathogenesis of multiple myeloma".
- 2020 Speaker at the Scientific Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma of the 62nd meeting of the American Society of Hematology (online, 3rd of December). Title of the talk: "Molecular/ Genomic Evolution of Multiple Myeloma".
- 2020 Speaker at the meeting "MultiLab: multiple round tables on Multiple Myeloma". (online, 24th of November). Title of the talk: "clonal evolution and genomics of plasam cell dyscrasias".
- 2020 Tutor at the second edition of Master in management del Mieloma Multiplo by the European Myeloma Network (online, 19th of November)
- 2020 2nd Society of Hematological Oncology (SOHO) Italian conference (Rome, 22nd-24th of September). 15th session: Multiple Myeloma – MRD, Biology and near future. Title of the talk: Genetic profiling of Multiple Myeloma in novel agents era



- 2020 Inaugural meeting on advances in myeloma precursor conditions in the 21st century (Online, 20th of August): Session on genomics of SMM. Title of the Talk: Genomic markers using WGS
- 2020 Strategies of treatment of Multiple Myeloma: towards personalization of care (Brescia, 31st of January): "genetic heterogeneity of multiple myeloma".
- 2020 24th European Multiple Myeloma Academy (Wien, 23-25 January): "Molecular pathogenesis of multiple myeloma".
- 2019 Highlights from IMW (Bologna, 19-20 November): "Genomic profile of MGUS and smoldering MM".
- 2019 47° congresso della Società Italiana di Ematologia (Rome, 7-9 October): "Applicazioni cliniche della medicina di precisione in ematologia neoplastica".
- 2019 Corso Educazionale from bench to bedside nel mieloma multriplo (Padova, 24 September): "Minimal Residual Disease nel Mieloma Multiplo: dalla biologia alla clinica".
- 2019 What's next in multiple myeloma (Catania, 23 September): "The role of next-generation sequencing in multiple myeloma"
- 2019 Progetto Ematologia Emilia Romagna (Cesena, 21 September): "la multiclonalità delle malattie ematologiche e la loro evoluzione clonale"
- 2019 17th international myeloma society annual meeting (Boston, 12-15 September): "Genomic Profiling: How is MGUS/SM different from Active MM?"
- 2019 24o congresso della European Haematology Association (Amsterdam, 13-16 June). "Clonal heterogeneity in Multiple Myeloma"
- 2019 Next Generation Sequencing Dal laboratorio alla pratica clinica: un percorso ad ostacoli? Terza Edizione (Milan, 3 April)
- 2018 Multiple myeloma and related malignancies (Bari 8-10 November)
- 2018 MD Anderson Cancer Center Leukemia and Lymphoma. Europe and the USA: Linking Knowledge and Practice (Dubrovnik, 5 October)
- 2018 Seminari di Aggiornamento in Ematologia Neoplastica (Rionero in Vulture, 27 September)
- 2018 SIES Discutiamone insieme: Le Sfide Della Medicina Di Precisione In Ematologia (Bologna, 28 June)
- 2018 1° Myeloma-Lab Workshop: Esperienze Ed Aggiornamenti Dai Laboratori (Miltenyi Biotech, Bologna 31 May)
- 2017 Università degli Studi di Milano, Center for Complexity & Biosystems (Milan, 14 December)
- 2017 9° Meeting Triveneto sul Mieloma e Gammopatie Monoclonali (Padova, 9-10 November)
- 2017 NGS nella pratica clinica oncologica (Cagliari, 25 May)
- 2017 Novel Insights In Biology Myeloma: The Seed And Soil (Catania, 17-18 February)
- 2016 Ospedale San Raffaele (Milan, 14 March)
- 2016 "POST-ORLANDO 2015" Novità dal Meeting della Società Americana di Ematologia (Genova, 12 February)



Niccolò Bolli

- 2016 Università di Bologna, Istituto di Ematologia "L.A.Seràgnoli" (Bologna, 10 February)
- 2015 La Gestione del Paziente con Mieloma Multiplo (Milan, 23 June)
- 2015 SIES Discutiamone insieme: Basi molecolari dalla progressione neoplastica e della farmaco-resistenza nel Mieloma Multiplo (Florence, 19 March)
- 2015 Stage Mieloma Multiplo (Milan, 12 March)
- 2014 Istituto Clinico Humanitas (Milan, 7 March).
- 2014 Istituto Nazionale Tumori (Milan, 15 January).
- 2014 LLRs Trials Acceleration Programme (TAP) (London, 10 January).
- 2013 "Molecular Pathology and Diagnosis of Cancer", Wellcome Trust Advanced Course (Hinxton, 10-15 November).
- 2013 B cell malignancies: the impact of biomarkers on treatment decisions (York, 10 May).
- 2013 6th International Symposium on the Biology and Immunology of Cutaneous Lymphoma - 2nd World Congress on Cutaneous Lymphoma (Berlin, 6-9 February).
- 2012 "Molecular Pathology and Diagnosis of Cancer", Wellcome Trust Advanced Course (Hinxton, 9-14 December).
- 2009 14o congresso della European Haematology Association (Berlin, 4-7 June). "NPM1 in-focus session"

Memberships	2022-present	International Myeloma Society – IMS (Member)
	2018-present	Italian Society of Hematology – SIE (Member)
	2016-present	Italian Society of Experimental Hematology – SIES (Member)
	2014-2016	Advisory Board of the charity "Damiano per l'ematologia"
	2013-present	Senior Member, St Edmunds College, Cambridge UK.
	2009-2012	American Society of Hematology (Member).
	2007-present	European Hematology Association (Member).

Personal information I authorize the handling of personal information in this curriculum, according to D.Lgs n. 196/03 and following modifications and Regulations EU 679/2016 (General Regulations concerning Data Protection or GRDP)

Date 06/11/2023

Signature